Objective response in amyloidosis treated with intermittent chemotherapy

Area of Science:

• Hematology
• Oncology
• Nephrology

Background:

• Light chain amyloidosis is a rare plasma cell disorder.
• It can affect multiple organs, including the liver, spleen, and bones.

Observation:

• A 37-year-old woman presented with hepatosplenomegaly, elevated alkaline phosphatase, and destructive bone lesions.
• These symptoms were indicative of advanced amyloidosis.

Findings:

• Intermittent chemotherapy with melphalan and prednisone over 44 months resulted in disease regression.
• This case confirms the potential efficacy of cytotoxic chemotherapy in managing light chain amyloidosis.

Implications:

• Cytotoxic chemotherapy can be an effective treatment option for select patients with light chain amyloidosis.
• Further research is warranted to optimize treatment strategies and improve patient outcomes.